Marksans Pharma has received FDA approval for its Benzonatate capsules, enabling them to introduce this medication into the U.S. market with two available strengths: 100 mg and 200 mg.

Marksans Pharma has secured approval from the US FDA to market Benzonatate Capsules, a treatment for coughs and respiratory infections in the United States. This development expands their reach into the American market.

Marksans Pharma experienced a 7.9% surge in shares due to USFDA approval for a generic version of Tessalon (Benzonatate Capsules), previously owned by Pfizer. The company's Q3FY26 net profit increased significantly to ₹11,320.2 crore, with revenue growth of 10.6% YoY, attributed to strong execution and favorable market conditions.

Marksans Pharma has received U.S. FDA approval for Benzonatate Capsules, expanding their product portfolio in the American market. This approval could potentially increase their market presence and revenue stream in the US pharmaceutical sector.